WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the Company will present at the Cambridge Health Institute’s (CHI) 5th Annual Antibacterial Drug Development Conference “Resistance is Futile: The Challenge of Antibacterial Drug Development.” Joyce Sutcliffe, Ph.D., Tetraphase Senior Vice President, Biology, will present at 4:00 p.m. on April 12, 2011 on how Tetraphase’s drug candidates target pathogens resistant to currently used antibiotics.
